BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value

$416.54+0.58 (+0.14%)

Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –

BeOne Medicines EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

BeOne Medicines's EV/EBITDA was 40.4× on Nov 11, 2026, against 101.8× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	40.4×	−49.4
2025	Dec 31, 2025	89.7×	–

Parsed from the XBRL in BeOne Medicines's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ONC.

Revenue growth32.9% · median 5.1%

Gross margin89.4% · median 64.4%

Operating margin17.8% · median 11.4%

Net margin13.9% · median 4.7%

Advertisement
300 × 250

See a number that looks wrong?